Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein
- PMID: 9725246
Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein
Abstract
The attachment glycoprotein (G) of respiratory syncytial virus (RSV) is synthesized as two mature forms: a membrane-anchored form and a smaller secreted form. Mutant cDNAs were constructed that encoded one or the other form of the protein and were expressed in recombinant vaccinia viruses (rVV). Mice were immunized with rVV by dermal scarification or i.p. injection to determine the contribution of the membrane-anchored and secreted forms of the G protein on the augmentation of pulmonary pathology seen following RSV challenge. Mice scarified with rVV expressing the membrane-anchored G protein had a markedly reduced pulmonary eosinophilic response following RSV challenge compared with mice scarified with rVV expressing either wild-type or secreted G protein. The induction of pulmonary eosinophilia in rVV-primed mice was also dependent upon the route of vaccination. An eosinophilic response was not observed in any groups of mice immunized i.p. with rVV expressing any of the different forms of the G protein. The difference in pulmonary pathology observed between dermal scarification or i.p. vaccinated mice was not reflected in a difference in cytokine production by splenocytes from vaccinated and challenged mice restimulated with RSV in vitro. Both groups produced significant levels of IL-4 and IL-5. These data suggest that the local APCs and lymphoid environment, together with the form of the G protein, influence pulmonary pathology following RSV challenge.
Similar articles
-
Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge.J Virol. 1999 Dec;73(12):10086-94. doi: 10.1128/JVI.73.12.10086-10094.1999. J Virol. 1999. PMID: 10559323 Free PMC article.
-
Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.Virology. 2000 Mar 30;269(1):54-65. doi: 10.1006/viro.2000.0186. Virology. 2000. PMID: 10725198
-
Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection.J Immunol. 1998 Dec 1;161(11):6215-22. J Immunol. 1998. PMID: 9834108
-
Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S46-57. doi: 10.1097/01.inf.0000108192.94692.d2. Pediatr Infect Dis J. 2004. PMID: 14730270 Review.
-
The effect of IL-12 treatment on vaccine-enhanced illness during infection with respiratory syncytial virus.Dev Biol Stand. 1998;92:179-85. Dev Biol Stand. 1998. PMID: 9554273 Review.
Cited by
-
Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection.J Virol. 2008 Mar;82(5):2350-7. doi: 10.1128/JVI.02372-07. Epub 2007 Dec 19. J Virol. 2008. PMID: 18094185 Free PMC article.
-
The role of Th17 and Treg responses in the pathogenesis of RSV infection.Pediatr Res. 2015 Nov;78(5):483-91. doi: 10.1038/pr.2015.143. Epub 2015 Aug 12. Pediatr Res. 2015. PMID: 26267154 Review.
-
Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge.J Virol. 1999 Dec;73(12):10086-94. doi: 10.1128/JVI.73.12.10086-10094.1999. J Virol. 1999. PMID: 10559323 Free PMC article.
-
The soluble form of human respiratory syncytial virus attachment protein differs from the membrane-bound form in its oligomeric state but is still capable of binding to cell surface proteoglycans.J Virol. 2004 Apr;78(7):3524-32. doi: 10.1128/jvi.78.7.3524-3532.2004. J Virol. 2004. PMID: 15016875 Free PMC article.
-
Layer-by-Layer Microparticle Vaccines Containing a S177Q Point Mutation in the Central Conserved Domain of the RSV G Protein Improves Immunogenicity.Viral Immunol. 2025 Apr;38(3):107-119. doi: 10.1089/vim.2024.0084. Epub 2025 Mar 24. Viral Immunol. 2025. PMID: 40126409
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous